Gov. Mike DeWine included dental offices in the first round of businesses that could reopen on May 1. The Centers for Disease Control and Prevention, the American Dental Association, and the Centers for Medicare and Medicaid Services have all issued warnings that non-emergency dental procedures should wait for now.

How do transportation agencies apply principles of green infrastructure (GI) to roadside water management? TRB is hosting a webinar on Monday, May 18, 2020 from 2:00 to 3:30 PM Eastern that aims to answer this question. Presenters will identify how GI may be used to mitigate impacts of flooding, drought, and temperature extremes that affect infrastructure. This webinar draws on research from the National Cooperative Highway Research Program (NCHRP) Domestic Scan Program 16-02: Leading Landscape Design Pr...

TRB's Airport Cooperative Research Program (ACRP) WebResource 5: Tools and Case Studies for NextGen for Airports is a companion to the five-volume ACRP Report 150: NextGen for Airports. It provides downloadable engagement materials from the NextGen Outreach Toolkit, discussed in Volume 2: Engaging Airport Stakeholders, and the Public Information Toolkit, discussed in Volume 3: Resources for Airports. A table that identifies the volume and page number of all case studies discussed in the five volumes is a...

As demand for air travel grows, airport-related emissions are increasing and airports are challenged to reduce associated environmental impacts. In response, expanded regulatory programs and global climate protection initiatives are being developed that require the aviation industry—including U.S. airports—to implement new, clean technologies and to modify operational practices to reduce emissions. One effective option for reducing the emissions associated with aircraft auxiliary power units (APUs) and d...

Most U.S. state departments of transportation (DOTs) are collecting weigh-in-motion data with a wide variety of sensor types and using them in a variety of applications. Many agencies use WIM data to aid in pavement design, although most are not currently using a Pavement ME (mechanistic-empirical) Design application. WIM for bridge and asset management purposes is used much less often. The TRB National Cooperative Highway Research Program's NCHRP Synthesis 546: Use of Weigh-in-Motion Data for Pavement, ...

A report from the Office of the Inspector General at the U.S. Department of Transportation

Self-consolidating concrete (SCC) is a highly flowable, nonsegregating concrete that is placed without any mechanical consolidation. TRB will conduct a webinar on Thursday, June 11, 2020, from 1:00 PM to 3:00 PM Eastern to discuss how SCC may be used to fill heavily congested or irregularly shaped members in bridge applications more easily while providing improved in-place quality and surface finish.The use of SCC may also decrease construction costs due to the reduced labor requirements during construct...

Does your organization know how to measure and verify pavement surface condition data based on mapping sensor technologies? TRB will conduct a webinar on Wednesday, June 10, 2020, from 1:00 PM to 3:00 PM Eastern to discuss the challenges and solutions from experience on actual projects. In pavement management systems, accurate and precise condition data are essential for making data-driven decisions about maintenance and rehabilitation projects. Some condition data, including surface cracking and other d...

The needs of airports may vary depending on the types of operations typically conducted at the airport, as well as the type of weather common to the airport. The TRB Airport Cooperative Research Program's ACRP Syntheis 105: Airport Surface Weather Observation Options for General Aviation Airports aims to provide the operators of general aviation (GA) airports a comprehensive source of information about airport-based weather observation options so they may make informed decisions to support the specific o...

Removed From Troubles (Open for application) Goodreads.com

"America's Funniest Home Videos" will resume the remainder of season 30 the following week at 7:00/6:00c.

Initially, the new season was slated to premiere Wednesday, June 17.

"Cisco Webex" email scam removal guide

What is the "Cisco Webex" scam email?

"Cisco Webex" is an email phishing scam. These letters claim to be official mail the Cisco Webex Team, stating that issues have been detected with recipients' Webex Mettings SSL certificates; therefore, their accounts must be verified. Cisco Webex is the name of a legitimate company, developing web conferencing and videoconferencing software. While the scam emails closely copy the graphic design and formatting of genuine Cisco Webex Team letters, they are illegitimate. If recipients attempt to log-in via link presented in the fake email to rectify the nonexistent problems, they are redirected to a phishing website that looks identical to the legitimate Webex Meetings log-in page. It is noteworthy that there has been an increase in scams/infections centering Cisco Webex services/products.

Just released first images from the National Science Foundation's Daniel K. Inouye Solar Telescope reveal unprecedented detail of the Sun's surface and preview the world-class products to come from this preeminent 4-meter solar telescope. NSF's Inouye Solar Telescope, on the summit of Haleakala, Maui, in Hawai'i, will enable a new era of solar science and a leap forward in understanding the Sun and its impacts on our planet.

Just when it seemed like robots couldn't get any cooler, Cornell University researchers have created a soft robot muscle that can regulate its temperature through sweating.

The closing panel in The Listening Lounge at February's Splore festival was a fairly ambitious one, I wasn't sure whether it was going to work and I knew I was going to depend on my panelists – a psychologist, a brilliant young Zimbabwean New Zealander, an evangelical pastor and a campaign expert – to make it work.
I'm never really sure after these discussions what's actually happened – I've spent the whole time in the moment. But re-reading the transcript (thank you to Emma Hart for that), I felt good about it.
I also felt that the subtitle: "How do we all move…

I got my sweet Jess for my birthday 14 years ago. Little did I know at the time that she would become my everything, the love of my life. She died 5 weeks

EPISODE SUMMARY This week, Dave and Brad talk about the best Content Management System (CMS) for publishing webcomics. Toocheke is brand new, and Brad's a big fan. EPISODE NOTES Today's show is brought to you by Wacom — makers of the incredible Wacom One! This week, Dave and Brad talk about the best Content Management System (CMS) for publishing webcomics. Toocheke is brand new, and Brad's a big fan. Questions asked and topics covered... Toocheke i

Feeling isolated? Perhaps a crossword puzzle will help. Click on the image to do the crossword puzzle on line, or click here for a printable pdf. If you do the puzzle on line, you can click the “submit” button to bring up a form where you can enter your name and submit your solution. I […]

You may recall in the early days of the pandemic, that pharma giant Gilead Sciences -- which has been accused of price gouging and (just last year!) charging exorbitant prices on drug breakthroughs developed with US taxpayer funds -- was able to sneak through an orphan works designation for its drug remdesevir for COVID-19 treatment. As we pointed out, everything about this was insane, given that orphan works designations, which give extra monopoly rights to the holders (beyond patent exclusivity), are meant for diseases that don't impact a large population. Gilead used a loophole: since the ceiling for infected people to qualify for orphan drug status is 200,000, Gilead got in its application bright and early, before there were 200,000 confirmed cases (we currently have over 1.3 million). After the story went, er... viral, Gilead agreed to drop the orphan status, realizing the bad publicity it was receiving.

After a brief dalliance with chloroquine, remdesivir has suddenly been back in demand as the new hotness of possible COVID-19 treatments. Still, a close reading of the research might give one pause. There have been multiple conflicting studies, and Gilead's own messaging has been a mess.

On April 23, 2020, news of the study’s failure began to circulate. It seems that the World Health Organization (WHO) had posted a draft report about the trial on their clinical trials database, which indicated that the scientists terminated the study prematurely due to high levels of adverse side effects.

The WHO withdrew the report, and the researchers published their results in The Lancet on April 29, 2020.

The number of people who experienced adverse side effects was roughly similar between those receiving remdesivir and those receiving a placebo. In 18 participants, the researchers stopped the drug treatment due to adverse reactions.

But then...

However, also on April 29, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that their NIH trial showed that remdesivir treatment led to faster recovery in hospital patients with COVID-19, compared with placebo treatment.

“Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo,” according to the press release. “Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo.”

The mortality rate in the remdesivir treatment group was 8%, compared with 11.6% in the placebo group, indicating that the drug could improve a person’s chances of survival. These data were close to achieving statistical significance.

And then...

“In addition, there is another Chinese trial, also stopped because the numbers of new patients with COVID-19 had fallen in China so they were unable to recruit, which has not yet published its data,” Prof. Evans continues. “There are other trials where remdesivir is compared with non-remdesivir treatments currently [being] done and results from some of these should appear soon.”

Gilead also put out its own press release about another clinical trial, which seems more focused on determining the optimal length of remdesivir treatment. Suffice it to say, there's still a lot of conflicting data and no clear information on whether or not remdesevir actually helps.

Still, that hasn't stopped people from trying to figure out just how much Gilead will price gouge going forward:

The Institute for Clinical and Economic Review (ICER), which assesses effectiveness of drugs to determine appropriate prices, suggested a maximum price of $4,500 per 10-day treatment course based on the preliminary evidence of how much patients benefited in a clinical trial. Consumer advocacy group Public Citizen on Monday said remdesivir should be priced at $1 per day of treatment, since “that is more than the cost of manufacturing at scale with a reasonable profit to Gilead.”

Some Wall Street investors expect Gilead to come in at $4,000 per patient or higher to make a profit above remdesivir’s development cost, which Gilead estimates at about $1 billion.

So... we've got a range of $10 to $4,500 on a treatment that we don't yet know works, and which may or may not save lives. But, given that we're in the midst of a giant debate concerning things like "reopening the economy" -- something that can really only be done if the public is not afraid of dying (or at least becoming deathly ill) -- the value to the overall economy seems much greater than whatever amount Gilead wants to charge. It seems the right thing to do -- again, if it's shown that remdesevir actually helps -- is to just hand over a bunch of money to Gilead, say "thank you very much" and get the drug distributed as widely as possible. Though, again, it should be noted that a decent chunk of the research around remdesevir was not done or paid for by Gilead, but (yet again) via public funds to public universities, which did the necessary research. The idea that it's Gilead that should get to reap massive rewards for that seems sketchy at best. But the absolute worst outcome is one in which Gilead sticks to its standard operating procedure and prices the drug in a way that millions of Americans can't afford it, and it leads to a prolonging/expanding of the pandemic.

Six months ago, which feels like roughly an eternity at this point, we discussed how Jerry Seinfeld and others won an absolutely ludicrous copyright suit filed against them by Christian Charles, a writer and director Seinfeld hired to help him create the pilot episode of Comedians In Cars Getting Coffee. What was so strange about the case is that this pilot had been created in 2012, whereas the lawsuit was only filed in 2018. That coincides with Seinfeld inking a lucrative deal with Netflix to stream his show.

It's not the most well known aspect of copyright law, but there is, in fact, a statute of limitations for copyright claims and it's 3 years. The requirement in the statute is that the clock essentially starts running once someone who would bring a copyright claim has had their ownership of a work disputed publicly, or has been put on notice. Seinfeld argued that he told Charles he was employing him in a work-for-hire arrangement, which would satisfy that notice. His lawyers also pointed out that Charles goes completely uncredited in the pilot episode, which would further put him on notice. The court tossed the case based on the statute of limitations.

For some reason, Charles appealed the ruling. Well, now the Court of Appeals has affirmed that lower ruling, which hopefully means we can all get back to not filing insane lawsuits, please.

We conclude that the district court was correct in granting defendants’ motion to dismiss, for substantially the same reasons that it set out in its well-reasoned opinion. The dispositive issue in this case is whether Charles’s alleged “contributions . . . qualify [him] as the author and therefore owner” of the copyrights to the show. Kwan, 634 F.3d at 229. Charles disputes that his claim centers on ownership. But that argument is seriously undermined by his statements in various filings throughout this litigation which consistently assert that ownership is a central question.

Charles’s infringement claim is therefore time-barred because his ownership claim is time-barred. The district court identified two events described in the Second Amended Complaint that would have put a reasonably diligent plaintiff on notice that his ownership claims were disputed. First, in February 2012, Seinfeld rejected Charles’s request for backend compensation and made it clear that Charles’s involvement would be limited to a work-for-hire basis. See Gary Friedrich Enters., LLC v. Marvel Characters, Inc., 716 F.3d 302, 318 (2d Cir. 2013) (noting that a copyright ownership claim would accrue when the defendant first communicates to the plaintiff that the defendant considers the work to be a work-for-hire). Second, the show premiered in July 2012 without crediting Charles, at which point his ownership claim was publicly repudiated. See Kwan, 634 F.3d at 227. Either one of these developments was enough to place Charles on notice that his ownership claim was disputed and therefore this action, filed six years later, was brought too late.

And that should bring this all to a close, hopefully. This seems like a pretty clear attempt at a money grab by Charles once Seinfeld's show became a Netflix cash-cow. Unfortunately, time is a measurable thing and his lawsuit was very clearly late.

In Matthew 7:15-19, Jesus tells His disciples how to tell good teachers from bad teachers. He tells them to look at the fruit. Is Jesus telling people to look at the lives of other teachers to see if they have good works? No! Not at all. Listen to the study to see what Jesus IS teaching and why this is important for properly understanding the gospel.

Nobody reads this blog any more. But do read Kieran Healy.A fundamental lesson of Sociology is that, in the course...

Recent advancements in Machine Learning (ML) have taught us two main lessons: a large proportion of things that humans do can actually be automated, and that a substantial part of this automation can be done with minimal human supervision. One no longer needs to select features for models to use; in many cases people are … Continue reading Three Paper Thursday: Adversarial Machine Learning, Humans and everything in between →

'Seriously sometimes seems Google's moderators are only optimized to respond to social media outrage'

Three weeks after Google removed 49 Chrome extensions from its browser's software store for stealing crypto-wallet credentials, 11 more password-swiping add-ons have been spotted – and some are still available to download.…

It's a long, long buildup to CEO's soliloquy, it's a long way to go

Knowledge 2020 With the long flights, late nights and early starts, IT conferences might seem endless. But with the shift to the online format becoming standard, for now at least, participants might be spared the trial of endurance.…

Microsoft, Cisco, Google etc gang up to form Open RAN Policy Coalition

Some of America’s super-corps have remembered how the US became the dominant global technology force it is, and have vowed to use innovation over threats to counter Chinese dominance in 5G markets.…

Enterprise demand set to soften, offset tier-two cloud, telco sales

Global server shipments reached an industry record-breaking 3.3 million units in the first quarter of 2020, marking a 30 per cent year-on-year growth, Omdia analysts estimated this week.…

Update used wrong data type, causing Tinder to Spotify to fall over

A change in the Facebook SDK backend managed to crash many popular iOS apps that integrated the code library, used for implementing various Facebook services.…

Even Exchange’s marketing bod reckons tests of new Reply-All-stopper could be a career-defining moment

Microsoft may just have made Reply All storms a thing of the past, by adding a suitable blocker to Exchange in Office 365 environments.…

It's like three buses showing up at once carrying $8bn

India’s largest mobile carrier, Jio, has just scored a third new investor in three weeks!…

And now to avoid container sprawl costing you plenty

Microsoft has slipped out licensing details for SQL Server running in containers and it will likely encourage developers to be pretty diligent in their use of Redmond’s database.…

iGiant not only screwed up the wiring, it knew it was shipping dodgy gear, it is claimed

Apple is potentially facing a class-action lawsuit over the failure of displays on its MacBook Pro line.…

Virus knocks hackers online: Show will try going virtual amid pandemic

Annual Las Vegas hacker gathering DEF CON has officially called off its physical conference for this year due to the coronavirus pandemic.…